According to Gram Research analysis, updated 2026 European guidelines recommend personalizing Crohn’s disease treatment in children based on disease severity: high-risk patients should start anti-TNF medications immediately, while low-risk patients may try nutrition-based therapies first. The guidelines emphasize aiming for complete intestinal healing rather than just reducing symptoms, with regular blood monitoring to ensure medications work effectively.
European pediatric doctors have released updated guidelines for treating Crohn’s disease in children, based on research from 2018-2025. The new recommendations focus on personalizing treatment based on how serious each child’s disease is, using newer medications when needed, and aiming for complete healing of the intestines rather than just reducing symptoms. The guidelines emphasize that high-risk patients should start strong anti-inflammatory drugs early, while children with milder disease might benefit from special nutrition-based treatments first. These recommendations help doctors make better decisions about which treatments work best for each child.
Key Statistics
A 2026 systematic review by 27 European pediatric experts analyzed research from 2018-2025 and found that high-risk pediatric Crohn’s disease patients should receive anti-TNF therapy as first-line treatment with proactive therapeutic drug monitoring.
The updated ECCO-ESPGHAN guideline recommends exclusive enteral nutrition or the Crohn’s Disease Exclusion Diet with partial enteral nutrition as preferred induction options for children with low-risk luminal Crohn’s disease.
The 2026 guideline emphasizes ’treat-to-target’ principles, with long-term management goals including achieving endoscopic remission (complete intestinal healing), normal growth, improved quality of life, and reduction of bowel damage in pediatric Crohn’s disease patients.
The Quick Take
- What they studied: How doctors should best treat, monitor, and care for children with Crohn’s disease based on the latest medical evidence
- Who participated: A team of 27 pediatric gastroenterology experts from Europe reviewed thousands of research studies published between January 2018 and June 2025
- Key finding: Children with more serious Crohn’s disease should start powerful anti-inflammatory medications (anti-TNF drugs) right away, while children with milder disease might try special nutrition plans first before using medications
- What it means for you: If your child has Crohn’s disease, doctors now have clearer, evidence-based guidelines to personalize treatment. This means your child’s doctor can choose the best starting treatment based on how serious the disease is, potentially leading to better long-term outcomes and fewer complications
The Research Details
A team of 27 expert pediatric doctors from across Europe systematically reviewed all major medical research studies about treating Crohn’s disease in children published from January 2018 through June 2025. They searched three major medical databases (MEDLINE, EMBASE, and Cochrane Central) to find the best available evidence.
The experts then graded each study based on how reliable and trustworthy it was using a standard scientific ranking system. They created draft treatment recommendations and had two rounds of voting where the guideline panel, national representatives, and international specialists voted on each recommendation. A recommendation was accepted only if at least 80% of voters agreed it was sound advice.
This approach ensures the final guidelines represent the strongest scientific evidence available and have broad agreement among leading pediatric doctors across Europe.
These guidelines matter because Crohn’s disease in children is complex and can cause serious long-term problems if not treated properly. By systematically reviewing all recent research and getting expert agreement, these guidelines help doctors make consistent, evidence-based decisions rather than relying on older practices or individual preferences. This standardization improves outcomes for children across different countries and hospitals.
This is a high-quality guideline because it was developed by 27 recognized experts, reviewed recent research systematically, used a rigorous voting process requiring 80% agreement, and was published in a respected medical journal. However, it’s important to note that guidelines are recommendations, not absolute rules, individual children may need different approaches based on their specific situation. The guideline also acknowledges that some newer medications discussed aren’t yet officially approved for children, so doctors must use clinical judgment.
What the Results Show
The updated guidelines recommend a personalized approach based on disease severity. For children with high-risk Crohn’s disease (more severe inflammation, complications, or poor prognostic factors), anti-TNF medications should be started immediately as first-line treatment. These are powerful drugs that block a specific inflammatory protein in the body.
For children with low-risk luminal disease (milder inflammation limited to the intestinal tube), the guidelines recommend trying exclusive enteral nutrition (special liquid nutrition formulas) or the Crohn’s Disease Exclusion Diet combined with partial enteral nutrition as the first treatment approach. These nutrition-based strategies can reduce inflammation without medications in some children.
The guidelines emphasize ’treat-to-target’ principles, meaning doctors should aim for complete healing of the intestinal lining (endoscopic remission) rather than just reducing symptoms. This aggressive approach helps prevent long-term bowel damage and complications.
Therapeutic drug monitoring, regularly checking medication levels in the blood, is recommended for both starting treatment and ongoing management to ensure medications are working effectively and at safe levels.
The guidelines also address long-term management goals beyond just controlling inflammation: achieving normal growth and development, improving quality of life, and preventing permanent bowel damage. The recommendations review emerging advanced therapies including newer biologic drugs and small molecule medications that are increasingly used in clinical practice but not yet officially approved for children. The guidelines provide guidance on the roles of imaging (CT scans, MRI) and endoscopy (camera procedures) in monitoring disease and guiding treatment decisions.
These 2026 guidelines update previous recommendations by incorporating six years of new pediatric research (2018-2025) and integrating contemporary adult treatment principles. The shift toward ’treat-to-target’ and early aggressive therapy in high-risk patients reflects growing evidence that preventing intestinal damage early is more effective than waiting to treat complications. The increased emphasis on nutritional therapies for mild disease represents a more nuanced, personalized approach compared to older guidelines that recommended medications for most children.
This is a guideline based on systematic review of existing research, not a new research study, so it’s limited by the quality and quantity of pediatric studies available. Some newer medications discussed aren’t yet approved for children, so recommendations are based on adult data or limited pediatric evidence. The guideline acknowledges that individual children vary greatly, so recommendations must be adapted to each child’s specific situation. Additionally, access to specialized treatments and monitoring may vary by country and healthcare system.
The Bottom Line
Parents and doctors should work together to: (1) Assess disease severity early to determine if high-risk or low-risk treatment is appropriate; (2) For high-risk disease, start anti-TNF medications promptly; (3) For low-risk disease, consider nutrition-based treatment first; (4) Use regular blood tests to monitor medication levels; (5) Aim for complete intestinal healing, not just symptom improvement; (6) Monitor growth, nutrition, and quality of life alongside disease control. These recommendations have strong expert agreement (≥80% consensus) based on recent evidence.
These guidelines are specifically for children and teenagers with Crohn’s disease and their families. Pediatric gastroenterologists should use these to guide treatment decisions. General pediatricians can use these to understand current best practices and when to refer to specialists. Parents should discuss these recommendations with their child’s doctor to understand the treatment approach. These guidelines don’t apply to adults with Crohn’s disease, though some principles overlap.
Improvement timelines vary by treatment type. Nutrition-based therapies may show improvement in 2-4 weeks. Anti-TNF medications typically take 4-8 weeks to show full effect. Complete intestinal healing (endoscopic remission) may take 3-6 months or longer. Long-term benefits like normal growth and reduced complications develop over months to years of consistent treatment.
Frequently Asked Questions
What’s the best first treatment for Crohn’s disease in children?
Treatment depends on disease severity. High-risk children should start anti-TNF medications immediately. Low-risk children may try exclusive enteral nutrition (special liquid formulas) or the Crohn’s Disease Exclusion Diet first. Your child’s doctor will determine which approach fits their specific situation.
How do doctors know if Crohn’s treatment is working in kids?
Doctors use therapeutic drug monitoring, blood tests checking medication levels, to ensure drugs are working effectively. They also monitor symptoms, growth, nutrition status, and perform endoscopy (camera procedures) to check if the intestinal lining is healing. The goal is complete intestinal healing, not just symptom improvement.
Can nutrition alone treat Crohn’s disease in children?
For children with mild (low-risk) disease, nutrition-based therapies like exclusive enteral nutrition can be effective first-line treatment. However, children with more severe disease typically need anti-inflammatory medications. Nutrition remains important for all children with Crohn’s to support growth and healing.
What does ’treat-to-target’ mean for pediatric Crohn’s disease?
Treat-to-target means doctors aim for complete intestinal healing (endoscopic remission) rather than just reducing symptoms. This aggressive approach prevents long-term bowel damage and complications. It requires regular monitoring and medication adjustments to achieve and maintain this healing goal.
Are newer Crohn’s medications safe for children?
The guideline reviews emerging biologic and small molecule therapies increasingly used in practice, though most aren’t yet officially approved for children. Doctors use clinical judgment based on adult data and limited pediatric evidence. Discuss safety and benefits of any medication with your child’s specialist.
Want to Apply This Research?
- Track medication adherence (did your child take their medication as prescribed?), symptom frequency (bowel movements, pain, energy levels), growth measurements (height and weight monthly), and medication side effects. Record dates of blood tests for drug monitoring and endoscopy procedures.
- Use the app to set reminders for medication times, log daily symptoms to discuss with doctors, track nutrition intake if using enteral nutrition therapy, and record questions for doctor visits. Share tracked data with your child’s gastroenterology team to support personalized treatment adjustments.
- Establish a routine of weekly symptom logging, monthly growth tracking, and quarterly review of medication effectiveness with your doctor. Use the app to maintain a timeline of treatments tried, response to each, and any complications. This creates a clear picture of what works for your individual child over time.
This article summarizes clinical guidelines for healthcare professionals and informed patients. It is not medical advice. Crohn’s disease treatment must be individualized by a qualified pediatric gastroenterologist who knows your child’s complete medical history. Treatment decisions should be made collaboratively between your child’s medical team and family. Always consult your child’s doctor before starting, stopping, or changing any treatment. This guideline represents expert consensus but acknowledges that individual children may require different approaches based on their specific circumstances.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
